Targeting autophagy in multiple myeloma

Leuk Res. 2017 Aug:59:97-104. doi: 10.1016/j.leukres.2017.06.002. Epub 2017 Jun 3.

Abstract

Autophagy plays an important role in plasma cell ontogeny and in the pathophysiology of multiple myeloma. Autophagy is usually considered a pro-survival mechanism, and cooperates with the ubiquitin proteasome system in maintaining the homeostasis of myeloma cells by degrading excessive and misfolded proteins for energy recycling. Therefore, the inhibition of autophagy could effectively induce death in myeloma cells, and could synergize with proteasome inhibitors. However, the excessive activation of autophagy could also lead to the extreme degradation of the organelles that induce autophagic cell death. Hence, the activation of autophagic cell death might also represent a promising approach for treating myeloma. Recent studies have demonstrated that autophagy also mediates drug resistance in myeloma cells and the complications of myeloma, while the inhibition of autophagy may reverse the response to drugs. In this study, we have mainly reviewed recent research on autophagy in relationship to the therapeutic effect, the reversal of drug resistance, and the mediation of complications.

Keywords: Autophagic cell death; Autophagy; Complications; Drug resistance; Multiple myeloma.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects
  • Autophagy / drug effects*
  • Cell Survival / drug effects
  • Drug Resistance, Neoplasm / drug effects
  • Humans
  • Multiple Myeloma / diet therapy*
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / pathology*
  • Proteasome Inhibitors / pharmacology

Substances

  • Proteasome Inhibitors